|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CORRESPONDENCE It is with great interest that I read the report of Barlogie et
al1 on the use of thalidomide in patients with refractory multiple myeloma. It was concluded that there is a dose-response effect
with a higher response rate and a longer survival duration observed in
patients receiving more than a 42 g cumulative dose of thalidomide
in 3 months. That would be an average of close to 500 mg per day of
thalidomide taken by those high-risk patients. Here I present a case
that indicates the dose-response effect may not be present in
every case. The patient is a 66-year-old male who was diagnosed with
multiple myeloma (MM) in April 1998 when he presented with
shortness of breath (SOB) and fatigue. His disease progressed fairly
rapidly after initial melphalan plus prednisone (MP) and then
vincristine plus doxorubicin plus dexamethasone (VAD). He then
transferred his care to the University of New Mexico Cancer
Center in December 1999. Initial paraprotein level was 5.2 g/dL and a
thalidomide regimen was started at 400 mg per day. The dose
was decreased to 300 mg per day in the second month because of
intolerable somnolence, confusion, and sedation. While maintaining this
dosage, the paraprotein level dropped to a low point of 2.72 g/dL by
January 2001. By March 2001, the paraprotein level increased to 3.07 g/dL. For the 15 months he had been given thalidomide, he
continued to have side effects of mental confusion, mild sedation, and
difficulty in concentration. Because of the persistent side effects and
the rising paraprotein level, he requested to end the thalidomide regimen. By May 2001, the paraprotein level had increased to 3.47 g/dL
without thalidomide while the patient was feeling much better without
the previously mentioned central nervous system (CNS) toxicities. On further discussion, he agreed to try thalidomide again
but only at a much lower dose of 100 mg per day. A progressive drop of
his paraprotein level was observed for 8 consecutive months as shown in
Table 1. Overall CNS toxicity is also at
a much lesser degree for the patient at this low daily dose.
Dose escalation in elderly patients may be especially difficult as CNS toxicity could be severe even at a fairly low dose, no more than 200 mg per day. One 73-year-old male treated in the University of New Mexico Cancer Center started a thalidomide regimen at 200 mg per day in July 2000. The dose was decreased to 50 mg per day in less than one month secondary to side effects that included dizziness, confusion, and neuropathy. Even at 50 mg per day, he acknowledged that he skipped doses from time to time if he felt that he could not concentrate on his artwork. He is now into 11 months of treatment with a stable paraprotein level. It is correctly mentioned by Barlogie et al that how thalidomide achieve its anti-MM cells effect is unclear. It truly is a new and exciting treatment for MM that is quite different from all other chemotherapy agents at our disposal. As such, the use of thalidomide may also be different from how we traditionally dose other chemotherapy agents (eg, dose escalation to reach the maximum tolerance). Baidas et al2 reported their phase 2 evaluation of thalidomide, 200 mg versus 800 mg per day, in patients with metastatic breast cancer. On the 800 mg arm, all patients had progressive disease before 8 weeks staging. On the other hand, there were 2 patients on the 200 mg arm with stable disease at the 8 week mark. Hideshima et al3 reported their study of how thalidomide overcomes drug resistance of human multiple myeloma cells to conventional therapy. The dose range among the 17 responding patients is 100 to 800 mg per day. Two patients were later taking only 50 mg per day and showed continued response. In summary, since the initial publication showing thalidomide is a good treatment option for patients with multiple myeloma, starting at 200 to 400 mg per day with a target dose of 600 or even 800 mg per day has become a common practice.4 However, for some patients, dose de-escalation may be necessary.
Fa-Chyi Lee
References
1.
Barlogie B, Desikan R, Eddlemon P, et al.
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
Blood.
2001;98:492-494
2.
Baidas S, Isaacs C, Crawford J, et al.
A phase II evaluation of thalidomide in patients with metastatic breast cancer.
J Clin Oncol.
2000;18:2710-2717
3.
Hideshima T, Chauhan D, Shima Y, et al.
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Blood.
2000;96:2943-2950
4.
Singhal S, Mehta J, Desikan R, et al.
Antitumor activity of thalidomide in refractory multiple myeloma.
N Engl J Med.
1999;341:1565-1571
Response:Thalidomide and thromboembolismDrach and colleagues report that thalidomide in combination with a variety of cytotoxic drugs is associated with the increased risk of deep-vein thrombosis (DVT) in malignant disorders. The development of thrombosis in cancer patients is multifactorial, and the role of these different factors in the thromboembolic events of patients treated with thalidomide is difficult to dissect. The incidence of DVT in myeloma patients treated with multiagent chemotherapy without thalidomide is approximately 10%.1 When thalidomide was introduced as a single agent for refractory myeloma, no significant increase in thromboembolic events was noted.2 Because of its minimal myelosuppressive effect and its activity in chemotherapy-refractory myeloma, the drug was combined with chemotherapy; in that setting an increased incidence of DVT was observed which could not be explained by other known prothrombogenic factors.3 The highest incidence was observed when thalidomide was given with vincristine, adriamycin, dexamethasone (VAD) or other regimens containing anthracyclines.2,4 We have treated more than 70 patients with multiple cycles of cytoxan, dexamethansone, etoposide, platinum (CDEP) plus thalidomide, and the observed incidence of DVT has been below 15%. Many factors can contribute to the development of thromboembolism in cancer patients, including age, performance status, presence of a central-vein catheter, history of previous DVT, recent surgery, hereditary hypercoagulable states, and as recently reported by our group, non-Factor V Leiden activated protein C resistance.5 All of these factors need to be taken into consideration before reaching any conclusion. Drach and colleagues report frequent thromboembolic episodes in mantle cell lymphoma patients treated with cyclophosphamide, vincristine, and prednisone (CHOP), thalidomide, and rituximab. Rituximab as a single agent has also been associated with DVT in non-Hodgkin lymphoma patients.6 Therefore, the contribution of thalidomide to the development of DVT is not clear. Moreover, this regimen is a combination of thalidomide with an anthracycline and a corticosteroid. These findings therefore do not support the conclusions reached by Drach and colleagues that thalidomide is the main offender in the development of DVT in malignancies.
Maurizio Zangari
References
1.
Barlogie B, Jagannath S, Desikan KR, et al.
Total therapy with tandem transplants for newly diagnosed multiple myeloma.
Blood.
1999;93:51-54
2.
Barlogie B, Desikan R, Eddlemon P, et al.
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
Blood.
2001;98:492-494
3.
Zangari M, Anaissie E, Barlogie B, et al.
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
Blood.
2001;98:1614-1615
4.
Osman K, Comenzo R, Rajkumar SV.
Deep venous thrombosis and thalidomide therapy for multiple myeloma.
N Eng J Med.
2001;344:1951-1952
5. Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C
resistance in the absence of factor V Leiden mutation is a common
finding in multiple myeloma and is associated with an increased risk of
thrombotic complications. Blood 6. Feuring-Buske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol. 2000;79:493-500[CrossRef][Medline] [Order article via Infotrieve].   CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
